University of Cagliari
didactic content
05 October 2020
Pharmacotherapy
- A.A. 2022-2023_Lezione introduttiva.pdf
- A.A. 2022-2023_Malattie neurodeg Alzheimer.pdf
- A.A. 2022-2023_Malattia di Parkinson.pdf
- A.A. 2022-2023_Parkinson's Disease_Therapies.pdf
- A.A. 2022-2023_Multiple sclerosis.pdf
- A.A. 2022-2023_Hugtington Disease.pdf
- A.A. 2022-2023_Anestetici.pdf
- A.A. 2022-2023_Ansiolitici.pdf
- A.A. 2022-2023_Antiepilettici.pdf
- A.A. 2022-2023_Antipsicotici.pdf
- A.A. 2022-2023_Psicostimolanti parte 2.pdf
- A.A. 2022-2023_Psicostimolanti parte 1.pdf
- A.A. 2022-2023_Antidepressivi.pdf
- A.A. 2022-2023_Antidepressivi 2.pdf
- A.A. 2022-2023_Tossicodipendenza.pdf
- A.A. 2022-2023_Oppioidi.pdf
- A.A. 2022-2023_Nicotina- Alcol.pdf
- A.A. 2022-2023_Terapie farmaci abuso.pdf
- A.A. 2022-2023_Cannabinoidi Allucinogeni.pdf
- A.A. 2022-2023_ANTINF -FANS.pdf
- A.A. 2022-2023_ANTINF-PG.pdf
- A.A. 2022-2023_Aspirina e altri FANS.pdf
- A.A. 2022-2023_farmaci PG e Artr-engl.pdf
- A.A. 2022-2023_Glucocorticoid immunospr.pdf
- A.A. 2022-2023_Emicrania.pdf
- A.A. 2022-2023_Emicrania.pdf
- A.A. 2022-2023_Gotta.pdf
- A.A. 2022-2023_H1 antagonists.pdf
- A.A. 2022-2023_Farmaci Apparato respiratorio.pdf
- A.A. 2022-2023_Farmaci Gastrointestinale.pdf
- A.A. 2022-2023_Anti-hyperlipidemic drugs.pdf
- A.A. 2022-2023_Osteoporosi dis erettile.pdf
- A.A. 2022-2023_Obesità.pdf
- A.A. 2022-2023_Anti-arrhythmic drugs.pdf
- A.A. 2022-2023_Anti-Angina Pectoris drugs.pdf
- A.A. 2022-2023_Anti-hypertensive drugs.pdf
- A.A. 2022-2023_Heart failure drugs.pdf
- A.A. 2022-2023_Terapia del-Covid.pdf
- A.A. 2022-2023_Terapia Covid_Dott.ssa giulia rapallo.pdf